Xenobiotic-Free Culture System To Expand Human Limbal Stem Cells

Tech ID: 27459 / UC Case 2017-431-0

Summary

UCLA researchers in the Departments of Opthalmology have developed a xenobiotic-free manufacturing process to produce transplantable human limbal stem cells for use in treating limbal stem cell deficiency.

Background

Limbal stem cell deficiency (LSCD) is a disorder characterized by the loss or dysfunctionality of limbal stem cells (LSCs) and its subsequent ability to regenerate the corneal epithelial surface. LSCD is characterized by persistent epithelial defects, conjunctivalization, neovascularization, scarring, and inflammation, all of which lead to corneal opacity, pain, photophobia, and ultimately blindness. Corneal transplantation is ineffective to treat severe to total LSCD because functional LSCs are not transplanted. The highest success rate of treating LSCD was achieved using single isolated LSCs cultured on 3T3 mouse fibroblasts feeder cells in a culture medium that contained fetal bovine serum (FBS). However, the presence of animal components in such xenobiotic culture systems poses a risk of transmitting animal diseases to human recipients after transplantation. There is a need for an effective and complete xenobiotic free culture system for culturing LSCs that minimizes the risk of cross-contamination and toxic effects when the LSCs are transplanted to the patient.

Innovation

Researchers at UCLA developed a xenobiotic-free manufacturing process to produce transplantable human limbal stem cells for use in treating limbal stem cell deficiency. This method does not require the use of toxic compounds such as cholera toxin (to promote LSC proliferation) or DMSO (to enhance membrane permeability). The researchers have defined an optimal media and growth protocol for these cells.

Applications

Transplant of LSCs in patients with limbal stem cell deficiency

Advantages

  • Does not contain xenobiotics: Eliminates risk of transmitting animal disease to recipient
  • Does not use cholera toxin or DMSO (to enhance membrane permeability)

Patent Status

Country Type Number Dated Case
United States Of America Published Application 20200123497 04/23/2020 2017-431
European Patent Office Published Application 3554487 10/23/2019 2017-431
 

Related Materials

Contact

Learn About UC TechAlerts - Save Searches and receive new technology matches

Inventors

  • Deng, Sophie X.

Other Information

Keywords

Limbal stem cells, cell culture, culture medium, xenobiotic-free, transplant, therapy, limbal stem cell deficiency, LSCD, cornea, opacity, blindness

Categorized As